News | November 18, 2013

Boston Scientific Announces First Commercial Implants of Lotus Valve System in Europe

Patients in Germany receive TAVI devices designed for total control, accurate deployment

heart valve repair hybrid or TAVI boston scientific lotus aortic repair system
November 18, 2013 — The first two commercial implants of the Boston Scientific Lotus Valve System have taken place in a German hospital. Gerhard Schuler, M.D. and professor, University of Leipzig, Leipzig, Germany and Axel Linke M.D. and professor Leipzig, led the procedures at the Heart Center — University Hospital Leipzig. CE mark approval for the Lotus Valve System was announced Oct. 28 at the Transcatheter Cardiovascular Therapeutics conference (TCT 2013) in San Francisco.
 
The Lotus Valve System offers an alternative treatment for patients with severe aortic stenosis at high risk of surgical valve replacement. It is a transcatheter aortic valve implantation (TAVI) device designed to give physicians total control throughout the TAVI procedure. The Lotus Valve is comprised of bovine pericardium and a nitinol frame with a central marker to aid in precise positioning. It features a novel Adaptive Seal technology to help minimize aortic regurgitation. It is also the first device of its kind that can be fully retrieved, redeployed or repositioned, even after full valve deployment and prior to release. 
 
"The Lotus Valve System permits very precise positioning of the device and the Adaptive Seal minimizes potential paravalvular leakage," said Schuler.  "These are the key differentiating features of this new technology."
 
Ian Meredith Ph.D., director, MonashHeart at Monash Medical Centre, Melbourne, Australia and principal investigator presented the primary endpoint data from the REPRISE II clinical trial at TCT 2013. The data demonstrated that the Lotus Valve System was successfully implanted and correctly positioned in all 120 patients, and met the co-primary endpoints of mean aortic valve pressure gradient and all-cause mortality at 30 days. The valve produced impressive clinical results with no valve malpositioning, migration or severe embolization, low clinical event rates that were consistent with those reported for other valves and negligible paravalvular aortic regurgitation at 30 days.
 
The Lotus Valve System comes pre-attached on a transfemoral delivery system and is inserted into the body through a small incision in the leg.  Once delivered across the diseased aortic valve, the Lotus Valve System is deployed through a controlled mechanical expansion that is distinct from balloon-expandable or self-expanding valves.
 
"The controlled mechanical expansion and early functioning of the valve facilitate precise positioning on the first attempt, and the ability to fully or partially recapture the valve, if necessary, provides additional assurance that the valve will be ideally positioned at the end of the procedure," said Linke. 
 
The Lotus Valve System is available at select centers in Europe with commercial site expansion accelerating as physicians and centers become fully trained. The valve is available in a 23 and 27 mm size, treating patients with aortic annulus sizes from 20 to 27 mm. The Lotus Valve System is an investigational device in the United States and Japan and is not available for sale.
 
"Completing our first commercial implants marks a key step forward in offering an advanced new technology in Europe,” said Tom Fleming, vice president and general manager, structural heart, Boston Scientific.” The Lotus Valve System has been designed to give the physician increased control during implantation and to help provide a more precise, predictable procedure. We believe the Lotus Valve is an important treatment alternative for severe aortic valve disease patients at high risk for surgical valve replacement."
 
For more information: www.bostonscientific.com

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Overlay Init